PROTACs have introduced a new way to selectively degrade proteins that were previously considered to be difficult to target with conventional small molecules.
By harnessing the ubiquitin-proteasome system, PROTACs promote protein degradation rather than merely inhibiting their function.
This mechanism potentially offers new therapeutic avenues for complex diseases such as cancer, neurodegenerative disorders and other conditions wherein protein regulation is crucial.
Kenneth Barr, Senior Vice President of Research Services, at Syngene International, reports.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.